Trials / Completed
CompletedNCT00933517
Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.
Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere® (Docetaxel) Plus Vectibix® (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Centre Jean Perrin · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination: "FEC-Taxotere/Vectibix".
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vectibix | 9mg/kg at D1 of each 21-days cycle |
| DRUG | fluorouracile | 500 mg/m2 at D1 of each 21-days cycle |
| DRUG | Epirubicine | 100 mg/m2 at D1 of each 21-days cycle |
| DRUG | cyclophosphamide | 500 mg/m2 at D1 of each 21 dyas cycle |
| DRUG | docetaxel | 100 mg/m2 at D1 of each 21 days cycle |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2009-07-07
- Last updated
- 2014-03-21
Locations
12 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00933517. Inclusion in this directory is not an endorsement.